MiCareo Inc.

MiCareo is pushing beyond the limits of current liquid biopsy technologies by providing high purity isolated live rare cells and automated multiplexed fluorescence imaging. We are building technologies to accelerate the way pharmaceutical companies monitor drug response & screen for drug effectiveness, and giving researchers the tools to find new correlations in biomarker expression using fully quantitative visual subtyping of each cell. What truly sets MiCareo apart is our combination of unique technologies to minimize sample preparation and preserve cell integrity in an automated instrument. We developed an assay to use the MiSelect R II System with a single-use microfluidic chip to directly detect the number of spike-receptor-binding domain (RBD)-specific MBCs in PBMCs. They provides consistent access to the raw materials (rare cells, CTCs, immune cells) necessary for medical researchers and drug developers to perform groundbreaking single-cell downstream analysis. We have spent over a decade innovating tools that can consistently capture, image, and deliver, living rare cells for downstream analysis. The MiSelect R II System provided a direct, automated, and quantitative method to isolate and analyze subsets of rare cells for tracking cellular immunity in the context of a rapidly mutating virus.